UCLA Health Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
ViewRay, Inc. (NASDAQ: VRAY) announced that UCLA Health has treated over 1,000 patients using the MRIdian MRI-guided radiation therapy system. This milestone places UCLA as the fourth MRIdian center globally. Since acquiring the technology in October 2014, UCLA has utilized the upgraded MRIdian Linac system, focusing on cancers like pancreatic and prostate. Key clinical trials, including the SMART Trial, emphasize MRIdian's role in enhancing radiation therapy precision. More than 14,300 patients have benefitted from MRIdian, with 45 systems in operation worldwide.
- UCLA Health exceeds 1,000 patients treated with MRIdian, enhancing its market presence.
- MRIdian technology supports advanced cancer treatment, particularly in precision and dose management.
- Strong clinical study backing, including SMART, MIRAGE, and EXCALIBUR trials validating MRIdian's effectiveness.
- Continuous patient treatment growth with 14,300 patients treated globally.
- None.
CLEVELAND, Aug. 17, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that UCLA Health joins the Siteman Cancer Center at Washington University, Seoul National University Hospital and Amsterdam UMC in surpassing the treatment of 1,000 patients using the MRIdian® MRI-guided radiation therapy system. UCLA Health is the fourth MRIdian center to reach this treatment milestone in bringing the benefits of MRI-guided radiation therapy to cancer patients.
UCLA Health was the third center in the world to acquire MRIdian technology, treating their first patient in October 2014. In 2019 the center upgraded to the MRIdian Linac system, which integrates MRI-guidance with linear accelerator delivery. UCLA Health treats a variety of cancers including pancreas, liver, and prostate. UCLA Health was a key collaborator in the development of the SMART Trial, a multi-center, prospective clinical trial for locally advanced or borderline pancreatic cancer. The trial explores the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer.
UCLA Health has pioneered the role of SBRT in prostate cancer over the past decade1 and is now further validating the role of MRIdian. UCLA has initiated two clinical studies including MIRAGE (NCT04384770) a randomized controlled trial of CBCT vs. MRIdian for safe SBRT for intact prostate, and the EXCALIBUR trial (NCT04915508) designed to assess the safety of MRIdian SBRT for patients with recurrent cancer after surgery.
"MRIdian is a highly refined SBRT device with particular ability to facilitate small treatment margins and to minimize dose to surrounding normal tissue and critical structures," said Michael L. Steinberg, M.D., Chair, UCLA Department of Radiation Oncology. "Throughout our years using the system, we've come to understand how much tumor and normal tissue deformation occurs during and between each treatment. We are able to address these critical changes in anatomy with MRIdian's on-table adaptive re-planning and real-time tissue tracking capabilities."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt to the targeted cancer in real-time. This combination allows physicians to define tight treatment margins based on the daily anatomy to support the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on fiducial markers. By enabling continuous tracking of the target and surrounding healthy tissue, MRIdian facilitates the automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
More than 14,300 patients have been treated with MRIdian. Currently, 45 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/
1. Kishan AU, et al.. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019 Feb 1;2(2):e188006.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. The results described herein may not be predictive.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, anticipated future orders, ViewRay's financial guidance for the full year 2021, anticipated future operating and financial performance, treatment results, therapy adoption, innovation and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
View original content:https://www.prnewswire.com/news-releases/ucla-health-treats-its-1-000th-patient-using-mridian-mri-guided-radiation-therapy-301356211.html
SOURCE ViewRay, Inc.
FAQ
What milestone did UCLA Health achieve with ViewRay's MRIdian system?
What types of cancer does UCLA Health treat with the MRIdian system?
How many patients have been treated with MRIdian globally?
What is the significance of the SMART Trial for ViewRay?
